Patent ID: 6696545
Filing Date: 2004-02-24
Classification: A61K,A61P,C07K

Abstract:
An oligopeptide defined by the parameters in Table 1, wherein said oligopeptide consists of the amino acid sequenceB-X-X-X-B-X-X-X-J-Tyrâ€ƒâ€ƒ(SEQ ID NO:41) wherein:B is Lys or Arg or the D-isomer thereof; X is any amino acid other than a charged or polar aliphatic amino acid or the D-isomer thereof, including norleucine; and J is Gly, Lys or Arg or the D-isomer thereof; wherein the amino acid residue at at least one terminus of said oligopeptide is optionally modified and wherein said oligopeptide comprises other than (a) a naturally occurring sequence of HLA-B &agr;1-domain 75-84, (b) a naturally occurring sequence of the transmembrane sequence of the human T cell receptor &agr; chain or (c) a mutated sequence of either (a) or (b) having not more than two mutations; and wherein said oligopeptide inhibits T cell proliferation or T cell mediated target cell lysis.